- Home
- CRGY vs NNNN Comparison
CRGY vs NNNN Comparison
Compare CRGY & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGY
- NNNN
- Stock Information
- Founded
- CRGY 1986
- NNNN 2021
- Country
- CRGY United States
- NNNN Germany
- Employees
- CRGY N/A
- NNNN N/A
- Industry
- CRGY Oil & Gas Production
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CRGY Energy
- NNNN Health Care
- Exchange
- CRGY Nasdaq
- NNNN Nasdaq
- Market Cap
- CRGY 2.2B
- NNNN 2.2B
- IPO Year
- CRGY N/A
- NNNN 2025
- Fundamental
- Price
- CRGY $8.93
- NNNN $42.80
- Analyst Decision
- CRGY Buy
- NNNN
- Analyst Count
- CRGY 11
- NNNN 0
- Target Price
- CRGY $16.50
- NNNN N/A
- AVG Volume (30 Days)
- CRGY 2.8M
- NNNN 147.4K
- Earning Date
- CRGY 08-04-2025
- NNNN 01-01-0001
- Dividend Yield
- CRGY 5.40%
- NNNN N/A
- EPS Growth
- CRGY N/A
- NNNN N/A
- EPS
- CRGY N/A
- NNNN 0.06
- Revenue
- CRGY $3,223,618,000.00
- NNNN $8,185,146.00
- Revenue This Year
- CRGY $27.16
- NNNN N/A
- Revenue Next Year
- CRGY N/A
- NNNN N/A
- P/E Ratio
- CRGY N/A
- NNNN $776.89
- Revenue Growth
- CRGY 31.58
- NNNN 21.95
- 52 Week Low
- CRGY $6.83
- NNNN $5.18
- 52 Week High
- CRGY $16.94
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- CRGY 48.22
- NNNN N/A
- Support Level
- CRGY $8.42
- NNNN N/A
- Resistance Level
- CRGY $9.69
- NNNN N/A
- Average True Range (ATR)
- CRGY 0.35
- NNNN 0.00
- MACD
- CRGY 0.05
- NNNN 0.00
- Stochastic Oscillator
- CRGY 53.94
- NNNN 0.00
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.